You are here

Home » Accelerator Programs » Phase I/II Infrastructure Grants

Phase I/II Infrastructure Grants

Doctors have identified a critical lack of funding for support personnel who speed up the process of enrolling children with cancer in clinical trials. With grants from Alex's Lemonade Stand Foundation, hospitals across the country have created new positions, specifically focused on filling this critical need, bringing the latest treatments to more children.

Please note that the Phase I/II Infrastructure grant is not offered every year. Please view our Grants Calendar for upcoming grant opportunities.

This grant is no longer offered.

Hospital for Sick Children

WhitlockThe Hospital for Sick Children (SickKids) is Canada's leading centre dedicated to advancing children's health through the integration of patient care, research and education. The cancer program at SickKids is one of the largest in North America, with about 375 new cancer diagnoses each year. SickKids has a strong legacy of participation in early-phase childhood cancer clinical trials through the COG Phase I program.

Principal Investigator Name: 

James Whitlock, MD

Project Title: 

SickKids MIBG and Phase I Leukemia Programs

Year Awarded: 

2011

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

University of Pittsburgh

Children's Hospital of Pittsburgh of UPMC (CHP), has a long-standing and solid tradition of contributing to early drug development for children with cancer.  Our institution is a member of the Children's Oncology Group (COG) Phase 1 Consortium and a charter member of the Pediatric Brain Tumor Consortium (PBTC).  We also participate in pharmaceutical studies as well as our own institutional new drug protocols and innovative pilot studies.  The program at Children's Hospital of Pittsburgh is the only pediatric Phase 1-2 (Developmental Therapeutics) program in the region including all of weste

Principal Investigator Name: 

A. Kim Ritchey

Project Title: 

Children's Hospital of Pittsburgh of UPMC Phase 1-2 Infrastructure Support Grant

Year Awarded: 

2011

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

University of Minnesota

Brenda Weigel

Read the latest about Dr. Weigel's research in a featured article, "Investing in Human Capital to Fast-Track Trials" found in ALSF's Spring 2014 newsletter.

Principal Investigator Name: 

Brenda Weigel, MD, MSc

Project Title: 

Phase I and II Clinical Research Program Infrastructure Award

Year Awarded: 

2011

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Dana-Farber CAncer Institute

Despite improvements in outcome over the last few decades, 15-20% of children with acute lymphoblastic leukemia and 40-50% with acute myelogenous leukemia ultimately succumb to their disease. Furthermore, current treatments result in many serious short- and long-lasting side effects. New and more effective therapies are urgently needed to increase cure rates and decrease treatment-related morbidity and mortality.

Principal Investigator Name: 

Lewis Silverman

Project Title: 

Development of a Childhood Leukemia Translational Research Program

Year Awarded: 

2011

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

University of Florida

In the US, 12,000 children will be diagnosed with cancer in 2010, and over 700 of those children will live in Florida. For families of children with a devastating diagnosis or a cancer that has recurred, the number of options for treatment may be small.  But no matter the outlook, every family deserves a chance to fight for the life of their child. SCH offers that hope through an ever-increasing number of early phase clinical trials.  Our team is now positioned to expand those offerings within a dedicated Innovative Therapy Program for pediatric oncology patients.

Principal Investigator Name: 

Amy Smith

Project Title: 

Expanding Hope: Innovative Therapy at Shands Children's Hospital

Year Awarded: 

2010

Cancer Research Category: 

Category of Grant: 

Institution: 

University of California San Francisco

Neuroblastoma is a highly malignant tumor of children that arises in the peripheral sympathetic nervous system, and spreads widely to bones and bone marrow.  The survival of children with metastatic neuroblastoma is less than 40%, despite intensive chemotherapy, radiation and bone marrow transplant. Metaiodobenzylguanidine (MIBG) is a chemical similar in structure to noradrenaline and specifically taken up by neuroblastoma, thus providing a means to detect tumor metastases and to deliver intravenous tumor-targeted radiation by attaching a radioactive iodine molecule.

Principal Investigator Name: 

Katherine Matthay, MD

Project Title: 

131 I-MIBG Imaging and Therapy for Neuroblastoma: Infrastructure Proposal

Year Awarded: 

2010

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Aflac Cancer Center and Blood Disorders Service of Children’s Healthcare of Atlanta

The Aflac Cancer Center at Children's Healthcare of Atlanta (CHOA) is one of the largest oncology programs in the United States and is a member of the NCI designated Comprehensive Cancer Center- Winship Cancer Institute of Emory University.  
 
Approximately 350 new patients (100-125 brain tumors) and 100 relapsed patients are seen each year.  In addition, CHOA serves as the statewide and southeastern referral center for phase I/II patients.   
 

Principal Investigator Name: 

Howard Katzenstein, MD

Project Title: 

Expansion of the Innovative Therapies Program to Include the Development of a Pediatric Neuro-Oncology Translational Research Program

Year Awarded: 

2010

Cancer Research Category: 

Category of Grant: 

Institution: 

Columbia University

The Children's Hospital of New York-Presbyterian at Columbia University has one of the largest pediatric oncology programs in the United States. Residing within this division is the Pediatric Cancer Foundation Developmental Therapeutics Program (PCFDTP) led by Dr. Julia Glade Bender. The PCFDTP has demonstrated scientific leadership in the field of translational antiangiogenic research through investigations of novel agents which inhibit tumor blood vessel growth by blocking vascular endothelial growth factor.

Principal Investigator Name: 

Julia Glade Bender, MD

Project Title: 

A New York Based Pediatric Oncology Developmental Therapeutics Program

Year Awarded: 

2010

Cancer Research Category: 

Category of Grant: 

Institution: 

Seattle Children's Hospital and Regional Medical Center

While an empiric strategy of evaluation of chemotherapeutic agents has resulted in impressive gains in survival of children with cancer, it is clear that the constantly increasing number of new agents requires a strategy in which early phase clinical trails are developed only when justified by strong pre-clinical laboratory data.

Principal Investigator Name: 

Russ Geyer

Project Title: 

Improving Development of and Patient Access to Early Phase Pediatric Cancer Clinical Trials

Year Awarded: 

2010

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Pages

Featured Hero

Erin Ersoy

Erin is a pre-veterinary student and a cancer survivor. When she was 2 years old she underwent difficult treatment for neuroblastoma, and lives with many health complications. But she's a star, shining light on childhood cancer by sharing her own story.
Read more »